logo

For the Inventor, By the Inventor

Princeton Junction, NJ, United States of America

Ru-Jen L Han

This inventor holds 9 USPTO granted patents. Top assignee: Hoffmann-La Roche Inc.. Active years: 1987-1995.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ru-Jen L Han. Retrieved from https://idiyas.com/inventor/ru-jen-l-han

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9

% Patents Active = 100.0

Average Co-Inventor Count = 3.4

ph-index = 6

Forward Citations = 141(Granted Patents)


Location History:

  • Princeton, NJ (US) (1990)
  • Princeton Junction, NJ (US) (1987 - 1995)

Company Filing History:

goldMedal9 out of 5,024 
 
Hoffmann-La Roche Inc.
 patents

Years Active: 1987-1995

Loading Chart...
9 patents (USPTO):Explore Patents
1. 5446189 - Intermediates for the production of N-substituted anilines, inhibitors (1995-08-29),
2. 5374772 - Substituted benzoic acids, inhibitors of phospholipases A.sub.2 (1994-12-20),
3. 5324747 - N-substituted anilines, inhibitors of phospholipases A.sub.2 (1994-06-28),
4. 5298652 - N-substituted glycines, inhibitors of phospholipase A.sub.2 (1994-03-29),
5. 5191108 - Catechol carboxylic acids (1993-03-02),
6. 5025036 - Catechol carboxylic acids (1991-06-18),
7. 4937373 - Substituted naphthalene carboxylic acids (1990-06-26),
8. 4937371 - Dihydroxynaphthalene derivatives (1990-06-26),
9. 4672066 - Derivatives of 4-acetyl-3-hydroxy-2-alkyl-phenoxycarboxylic acids (1987-06-09),

Title: The Innovative Contributions of Ru-Jen L Han

Introduction

Ru-Jen L Han is a notable inventor based in Princeton Junction, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that serve as inhibitors for various inflammatory diseases. With a total of 9 patents to his name, his work has had a profound impact on medical research and treatment options.

Latest Patents

Among his latest patents, Ru-Jen L Han has developed intermediates for the production of N-substituted anilines. These compounds are described as potent inhibitors of phospholipases A₂ (PLA₂'s), which are crucial in the treatment of inflammatory diseases such as psoriasis, inflammatory bowel disease, asthma, allergies, arthritis, dermatitis, gout, pulmonary disease, myocardial ischemia/reperfusion, and trauma-induced inflammation, including spinal cord injury. Another significant invention involves substituted benzoic acids that also act as inhibitors of phospholipases A₂, showcasing his innovative approach to addressing complex medical challenges.

Career Highlights

Ru-Jen L Han has built a successful career at Hoffmann-La Roche Inc., where he has been instrumental in advancing pharmaceutical research. His expertise in chemical compounds and their applications in treating inflammatory conditions has positioned him as a key figure in the industry. His dedication to innovation is evident in the patents he has secured, which reflect his commitment to improving patient outcomes.

Collaborations

Throughout his career, Ru-Jen L Han has collaborated with esteemed colleagues, including Ronald A LeMahieu and Mathew Carson. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and enhances the development of groundbreaking solutions in the pharmaceutical field.

Conclusion

Ru-Jen L Han's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his significant role in advancing medical treatments. His work continues to inspire future innovations in the industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…